29 results on '"del Poggio, P"'
Search Results
2. Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients
3. Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy
4. Health-economic evaluation of different organizational models to manage the Hepatitis C patient journey
5. Genotype 3 infection in DAA era: Preliminary reports of a real life northern Italy network for viral hepatitis
6. Cost-efficacy analysis of chronic hepatitis B treatment in a real-life setting of the Northern-Italy
7. Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis
8. F-39 Alpha-fetoprotein changes as surveillance test for hepatocellular carcinoma: results of a case-control study
9. T-12 Tenofovir suppressed viral suppression in most field practice, treatment-naïve patients with CHB followed for 3 years in a multicenter European study
10. T-11 5-year entecavir in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC
11. OC-15 Clinical validation of a sub-staging proposal of patients with intermediate HCC (BCLC-B)
12. P.15.2 ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT
13. OC.07.1 2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE
14. T-40 Alphafetoprotein and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre cohort study
15. T-8 Entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B from field practice: high efficacy and favorable safety profile over 3 years of treatment
16. T-9 2-year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice
17. P.1.48: EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 737 PATIENTS WITH CHRONIC HEPATITIS B
18. OC.09.2: MAINTAINED LONG-TERM SUPPRESSION OF HBV REPLICATION IN NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH ETV MONOTHERAPY IN FIELD PRACTICE: THE ITALIAN MULTICENTER EXPERIENCE
19. F-34 Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice: The Italian multicenter experience
20. F-36 Effectiveness and safety of tenofovir disoproxil fumarate in field practice: A multicenter European cohort study of 737 patients with chronic hepatitis B
21. T-4 A 20-years survey by ITA.LI.CA on hepatocellular carcinoma (HCC) in HCV-related cirrhosis
22. T-2 The evolving clinical scenario of hepatocellular carcinoma over the last 20 years in Italy
23. Transient elastography predicts response to prolonged therapy with a nucleoside analog in patients with chronic hepatitis B
24. Preliminary results of a screening program for the identification of cirrhotic patients in two Northern Italian areas with a high incidence of hepatocellular carcinoma (HCC)
25. Effectiveness of entecavir for the treatment of NUC-naïve chronic hepatitis B patients: A large multicenter cohort study in clinical practice
26. Transient elastography (TE) accurately predicts liver fibrosis stage in patients with chronic Hepatitis B
27. OC2.01.2 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) IN HEPATOCELLULAR CARCINOMA: WHEN IS IT WORTH DOING?
28. Early and very early HCC: When and how much does the treatment choice matter?
29. Surveillance for early diagnosis of hepatocellular carcinoma (HCC): Is it effective in intermediate/advanced cirrhosis?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.